2026 is the year of obesity pills from Novo Nordisk, Eli Lilly

The booming GLP-1 house was constructed on weekly injections. In 2026, new weight problems capsules will push the market into its subsequent chapter.

Sufferers are already getting their palms on the primary GLP-1 capsule for weight problems from Danish drugmaker Novo Nordisk — a once-daily drug that shares the identical model identify as its fashionable injection Wegovy. A GLP-1 capsule from the corporate’s chief rival Eli Lilly is not far behind, with a U.S. approval anticipated inside months. 

For some folks, capsules might function a extra handy — and doubtlessly cheaper — various to immediately’s blockbuster injections. The money costs of Novo Nordisk’s Wegovy capsule vary from $149 to $299 per thirty days, relying on the dose, which is barely lower than the newly lowered money costs of injections. 

Whereas the capsules aren’t anticipated to deliver extra weight reduction than weekly pictures, primarily based on separate medical trials, some well being consultants say increasing the vary of remedies might nonetheless be a serious win for sufferers.

Capsules might appeal to new sufferers to hunt weight problems therapy for the primary time, increasing the broader weight reduction and diabetes drug market and doubtlessly boosting gross sales for Novo Nordisk and Eli Lilly. The brand new customers might embody people who find themselves afraid of needles, in addition to sufferers who may gain advantage from current injections however do not view their situation as extreme sufficient to warrant a weekly shot.

“I feel that there are lots of people on the market who’ve by no means tried these GLP-1 medication and are possibly ready for the capsules to come back out,” mentioned Dr. Eduardo Grunvald, medical director of the UC San Diego Well being Middle for Superior Weight Administration. “It is type of a pure choice for some folks and even some prescribers.” 

“Secondly, if you must pay out of pocket, the capsules are going to be a bit inexpensive than the injections, in order that’s another excuse,” he mentioned. 

It is unclear precisely how many individuals are at the moment utilizing GLP-1s within the U.S., particularly for weight problems. However round 1 in 8 adults mentioned they have been taking a GLP-1 drug to shed extra pounds or deal with one other power situation as of November, based on a ballot from well being coverage analysis group KFF.

Now, capsules are rising as the following battleground for Novo Nordisk and Eli Lilly, which established the GLP-1 house that some analysts say could possibly be price virtually $100 billion by the 2030s. In August, Goldman Sachs analysts forecast that capsules might seize roughly 24% — or about $22 billion — of the worldwide weight-loss drug market by 2030.

This is how weight problems capsules might reshape the house.

Oral medication might pull new sufferers into the weight problems therapy market.

“I consider that it will fairly a bit increase the market,” Novo Nordisk CEO Mike Doustdar instructed CNBC in late December. “We all know from our family members and circles of pals that there are numerous individuals who nonetheless wouldn’t fairly take an injection … for this group of individuals, having a capsule choice is necessary.” 

Capsules might immediate some folks to start out weight problems therapy as a result of “they suppose it is in some way extra acceptable or approachable” than an injection, mentioned Dr. Caroline Apovian, co-director of the Middle for Weight Administration and Wellness at Brigham and Ladies’s Hospital. 

That does not imply a capsule would be the greatest match for everybody. However as soon as sufferers enter the health-care system for therapy, docs can information them by all choices – whether or not that is an injection, metabolic surgical procedure, or structured eating regimen and train packages, Apovian mentioned.

UCSD’s Grunvald mentioned uptake of weight problems capsules is prone to be pushed by main care physicians, who deal with nearly all of eligible sufferers and could also be extra comfy prescribing an oral drug.

Grunvald mentioned weight problems medication specialists, who care for under about 5% to 10% of eligible sufferers, usually tend to proceed favoring injections, which seem simpler than capsules primarily based on separate medical trials.

Deborah, a 53-year-old librarian in St. Louis, Missouri, mentioned she is curious in regards to the new Wegovy capsule partially due to its comfort issue. She declined to offer her final identify attributable to issues about stigma related to GLP-1s.

Deborah mentioned she would take into account an oral GLP-1 as a result of she is already accustomed to taking capsules for different prescriptions. She mentioned an oral drug would additionally deliver different advantages, like making journey simpler as a result of it will not require refrigeration, like injections do. 

She mentioned she can be within the doubtlessly decrease prices of capsules. Deborah has been taking weekly injections of Wegovy since June, and was paying $449 per thirty days in money earlier than Novo Nordisk lowered that value to $349 per thirty days. 

Price could possibly be an element for different sufferers, too.

Novo Nordisk’s capsule seems to have among the many lowest money costs out there, at $149 per thirty days for the beginning dose and $299 per thirty days for the 2 highest doses. Eli Lilly’s rival capsule is anticipated to have comparable pricing for cash-paying sufferers. 

These customers may also be capable to entry the beginning dose of each capsules for $149 per thirty days by President Donald Trump’s direct-to-consumer web site, TrumpRx, below a deal each corporations struck together with his administration in November. 

Weight problems injections have lengthy been laborious for sufferers to get, due partially to spotty insurance coverage protection and listing costs of roughly $1,000 per thirty days. Each Novo Nordisk and Eli Lilly have moved to deal with these issues by chopping money costs for his or her injectable medication to lower than half that quantity.

Eli Lilly in December mentioned the very best doses of single-dose vials of Zepbound will price $449 per thirty days for cash-paying sufferers, whereas Novo Nordisk in November mentioned practically all doses of Wegovy will price $349 per thirty days in money. 

These costs are nearer to the price of Novo Nordisk’s capsule, which can nonetheless be costly for some. However Grunvald mentioned the roughly $150 month-to-month distinction between the very best doses of Zepbound and Novo’s capsule “could possibly be an enormous distinction for many individuals” keen to pay out of pocket.

Sufferers with insurance coverage protection for Novo Nordisk’s oral drug pays as little as $25 per thirty days for the therapy. However capsules seemingly will not transfer the needle to spice up insurance coverage protection of GLP-1s for weight problems within the U.S. 

The direct-to-consumer money costs of Novo Nordisk’s oral drug are seemingly “considerably much less” than what employers and middlemen known as pharmacy profit managers would pay to cowl the medication, mentioned John Crable, senior vp of Company Synergies, an insurance coverage and worker advantages brokerage and consultancy.

Crable mentioned it’s unclear how a lot the capsule will in the end price payers comparable to employers since these costs are usually not publicly disclosed. But when they mirror injection prices — usually increased than $1,000 per thirty days — employers could also be reluctant so as to add the drug to their formularies, he mentioned. 

Some corporations that already provide protection of weight problems injections might add the capsules this 12 months. However Crable mentioned some employers have really dropped protection of GLP-1s for weight problems in 2026 attributable to their excessive prices.

“I do not see employers being extremely motivated so as to add what might be going to be one other excessive quantity, very excessive price drug to their formulary when the direct-to-consumer pricing for it’s so less expensive,” Crable mentioned. 

Drugmakers have tried to make a case that sufferers utilizing injections can change simply to oral medication. Eli Lilly in December launched information displaying that sufferers who initially took Wegovy or Zepbound pictures maintained nearly all of their weight reduction after switching to the corporate’s capsule. 

However Apovian, of Brigham and Ladies’s Hospital, mentioned price can be the one actual purpose to maneuver sufferers who’re doing nicely on injections to a capsule.

“If the [cash price] is comparable, I all the time favor the injectables as a result of I consider that the burden loss is healthier and the unwanted side effects are much less,” she mentioned.

Apovian mentioned she needs to see real-world information on how capsules carry out in contrast with injections, however separate late-stage trials already provide some clues.

Zepbound has proven common weight lack of greater than 20% in late-stage research. That is increased than outcomes seen with each the Wegovy injection and capsule in addition to Eli Lilly’s oral drug in separate trials. 

In those self same research, about 7% of sufferers or much less stopped therapy attributable to unwanted side effects from the Zepbound and Wegovy injections.

The Wegovy capsule confirmed comparable discontinuation charges, whereas about 10.3% of sufferers taking the very best dose of Eli Lilly’s oral drug stopped therapy due to unwanted side effects.

Leerink Companions analyst David Risinger mentioned sufferers with weight problems who have to lose a bigger share of their physique weight will seemingly keep on with injections, except they’ve a worry of needles.

Capsules, he mentioned, might primarily appeal to new sufferers who’re obese or mildly overweight and wish to obtain solely “modest” weight reduction.

Some sufferers at the moment utilizing weekly injections might attempt capsules, Risinger added, although not all will discover a each day oral choice extra handy.

That features Karen Galante, 42, of Horsham, Pennsylvania, who’s taking a compounded model of semaglutide – the energetic ingredient in Wegovy – which she mentioned is priced equally to Novo Nordisk’s new capsule.

Galante mentioned she doesn’t plan to change.

“It is laborious sufficient for me to recollect to take my nutritional vitamins each day,” she mentioned. “I just like the set-it-and-forget-it of taking one shot per week.” 

Risinger mentioned he expects each capsules from Novo Nordisk and Eli Lilly to “take off like a rocket” this 12 months. 

He famous that uptake might be better for the Wegovy capsule initially since Eli Lilly’s drug, orforglipron, is probably going nonetheless months away from getting into the market.

However Risinger mentioned he believes Eli Lilly’s capsule will in the end generate increased gross sales as a result of sufferers might take into account it extra handy.

Eli Lilly’s orforglipron is a small-molecule drug that’s absorbed extra simply within the physique and does not require dietary restrictions like Novo Nordisk’s capsule, which is a peptide treatment. Sufferers are imagined to drink not more than 4 ounces of water with the Wegovy capsule and should wait half-hour earlier than consuming or consuming anything every day. 

However Novo Nordisk’s CEO Doustdar has argued that these dietary necessities will not hinder uptake. He instructed CNBC in December it has not been a difficulty for the greater than one million people who find themselves taking the lower-dose model of the capsule for diabetes, marketed as Rybelsus, which entered the market in 2019. 

“Merely sip and go, and you are going to be effective,” Doustdar mentioned. “These individuals are waking up within the morning and taking their capsule with a glass of water, after which they do their regular each day routine half an hour later and transfer on with their life.”

He additionally known as the corporate’s drug the “most efficacious capsule,” saying that no different merchandise in growth have been in a position to present its identical degree of weight reduction in a late-stage trial. 

The best dose of Novo Nordisk’s Wegovy capsule helped sufferers lose as much as 16.6% of their weight on common at 64 weeks in a single late-stage research. That is similar to the injectable type of the drug. 

There aren’t any head-to-head research instantly evaluating that capsule with Eli Lilly’s. In one in every of Eli Lilly’s late-stage trials, the very best dose of its capsule helped sufferers lose 12.4% of their physique weight on common at 72 weeks. 

Regardless of that distinction in efficacy, Risinger mentioned the 2 capsules are considered as selling roughly comparable ranges of weight reduction. Some sufferers may not have to take the very best dose of both capsule, he added. 

In an August observe, Goldman analysts mentioned they count on Eli Lilly’s capsule to have a 60% share — or roughly $13.6 billion — of the each day oral phase of the market in 2030. They count on Novo Nordisk’s oral semaglutide to have a 21% share — or round $4 billion — of that phase. The analysts mentioned they count on the remaining 19% slice to go to different rising capsules.

Different drugmakers are racing to deliver their very own oral choices to the market, together with Pfizer, AstraZeneca, Construction Therapeutics and Viking Therapeutics. 

Risinger highlighted Construction’s each day oral GLP-1, which can enter part three trials later this 12 months. Shares of Construction soared greater than 100% on Dec. 9 after it launched midstage information displaying that its capsule, aleniglipron, helped sufferers with weight problems lose greater than 11% of their weight at 36 weeks, when adjusted for placebo. 

Further trial information confirmed {that a} increased dose of the capsule might ship better efficacy – greater than 15% weight reduction – surpassing the outcomes seen with the very best dose of Eli Lilly’s orforglipron. Nonetheless, the tolerability information, or how nicely sufferers tolerated Construction’s therapy, gave the impression to be worse than that of Eli Lilly’s capsule. 

In a launch on the time, Construction CEO Raymond Stevens mentioned the capsule could possibly be “doubtlessly best-in-class” for an oral small-molecule GLP-1. 

Risinger mentioned he expects that capsule and one other oral GLP-1 from AstraZeneca might launch as quickly as late 2028. 

He mentioned potential capsules which can be taken weekly, versus each day, and have “compelling profiles might tilt the steadiness extra in direction of orals” out there. 

Risinger pointed to privately held Verdiva Bio, which is creating a number of oral peptide remedies designed to be taken as soon as per week. That firm has an ongoing part two trial on an oral GLP-1.